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Abstract
Title- Effectiveness of 7.5 percent povidone iodine in comparison to 1 percent
clotrimazole in the treatment of otomycosis.
Key words- otomycosis, fungal otitis externa, fungi, antifungals, clotrimazole, povidone
–iodine, aspergillus, candida
Objectives
This was a prospective randomized case control study and its objective was to establish
the effectiveness of povidone iodine in treatment of otomycosis to a commonly used
antifungal, clotrimazole. Our secondary objective was to identify the most common
fungal isolate in our hospital. The two drugs were compared on the improvement in
symptoms and signs of the affected individuals.
Review of literature
Otomycosis or fungal otitis externa is a condition seen in any otolaryngology set up and
can be quite frustrating for the patient and the doctor due to its recurring nature. It is a
superficial, sub-acute or chronic infection of the outer ear canal, usually unilateral
characterized by inflammation, pruritus, pain and scaling (1). Prevalence is more in the
tropical and subtropical humid climates(4). Candida and aspergillus are the most common
fungi isolated (2). The most common aspergillus isolate was the niger species (3)(4)
followed by the species of flavus and fumigatus.
Treatment mainly comprises of thorough lavage of the ear and clearing all fungi debris
mainly seated in the anterior recesses of the ear canal (5). Predisposing factors must be
addressed and topical antifungals initiated. Clotrimazole is the most commonly used
antifungal. This drug acts on the fungal wall making them to be more permeable and lead
to their instability and later cell death(6).
Povidone iodine, is a widely used antiseptic, easily available, cheap and seen to be
effective in the treatment of bacteria, fungi, virus, protozoa and spores (7). No resistance
is known so far to this antiseptic (8). Hence we planned to use povidone iodine in this
study in view of its above properties.
Methodology
We conducted a prospective randomized case control study of individuals who were
clinically diagnosed with otomycosis in our ENT OPD. The individuals who satisfied the
inclusion criteria were randomized and blinded to the drug they would receive. The
symptoms and signs were noted and a pretreatment ear swab was taken for culture. On
follow up after 2 weeks, their symptoms, signs were noted and a post treatment ear swab
taken. Each of the pretreatment and post treatment variables were compared and efficacy
of the drug assessed.
Results and Conclusion
34 patients, clinically diagnosed as otomycosis who fulfilled the inclusion criteria were
assessed, 8 were lost to follow up.
In our study, the condition was more prevalent in females below the 30 age group.
Unemployed individuals topped the list followed by housewives. The left ear was most
commonly affected involving 74 % of the cases. Pruritus was seen in 76.5% of our
patients followed by otorrhoea. There was a close relation between self-cleaning and
absence of wax. Mixed infection was more common (35.4%) and aspergillus niger
formed 60.86% of fungal isolate. Pseudomonas aeruginosa and non-fermenting GNB was
the most common bacterial isolate. Both drugs showed a good response in symptoms and
signs after treatment and though comparable, were not statistically significant(p
value>0.05). The result of this study supports the use of Povidone-iodine in the treatment
of otomycosis, thus avoiding emergence of resistant organisms. Future studies in larger
groups of patients are necessary to see which is more effective. This study has opened a
window in the application of povidone –iodine in clinically diagnosed case of otomycosis
in humans in addition to the management of chronic suppurative otitis media.
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1INTRODUCTION
Fungal external otitis (otomycosis) is a common disease throughout the world. Its
frequency varies according to different geographic zones.  It is a prevalent disease in the
tropics (1) and is sometimes associated with complications, involving the middle ear (2).
It has been an entity which has perplexed many an otologist because of its recurrent
nature.
Since its description about 100 years ago by Andral and Cavarret in 1843 and by Mayer
in 1844, (3) many attempts have been made in the diagnosis and the treatment of this
condition. The disease is seen worldwide and it is estimated to constitute approximately
5-25% of the total cases of otitis externa (4).
In a routine otolaryngology clinic, its prevalence ranges from about 9 percent to about
30.4 percent in individuals presenting with otitis externa (5). It was believed that fungi
were secondary invaders in external canal infections and that one third of the external
otitis was caused due to fungi and the remaining were attributed to gram negative bacilli
(Syverton et al)(3).
Traditionally, the treatment of otomycosis revolved around good personal hygiene and
avoidance of self-cleaning. But the management varied as time progressed which ranged
from copious lavage to insertion of metacresylacetate wick, boric acid, sulphathiazole
ointment, topical ketoconazole, cresylate otic drops, and aluminum acetic drops in the
affected ear(5). In recalcitrant cases, treatment with 75 rads of X-rays (6) has also been
attempted. The use of metacresylacetate however had produced dermatitis and hence its
use was discontinued. The medical treatment has abundant literature describing the use of
various classes of drugs mainly antifungals in the topical treatment of otomycosis (7).
2However there has never been a study which evaluated the role of iodine as an antifungal
in otomycosis. It is a well-known fact that iodine is a routinely used antiseptic solution in
surgical wards, because of its antibacterial property which has never been resisted or
conquered by any organism. This present study plans to evaluate the antifungal (8)
property of povidone-iodine and to provide a cheaper alternative in the treatment of
otomycosis.
3AIMS AND OBJECTIVES
Aim
To evaluate the effectiveness of 7.5 percent povidone-iodine in the treatment of
otomycosis as compared to 1 percent clotrimazole ear drops.
Objectives
Primary Objective:
1. To establish the effectiveness of povidone iodine in the treatment of otomycosis in
comparison with clotrimazole.
Secondary Objective:
1. To establish povidone iodine as an antifungal agent.
2. To establish the most common fungal isolate in our hospital set up.
3. To detect the presence of any other pathogen.
4REVIEW OF LITERATURE
Otomycosis or fungal infection of the ear has been described since time immemorial. A
number of studies have been done on the epidemiology, geographical distribution and
clinical features of this disease and its association with chronic middle ear infection (7).
It has many synonyms such as Singapore ear, hot weather ear and mildew ear. Since the
early 1950s, there has been increasing awareness of this entity (Sood et al 1967,
Mugliston and O`Donoghue), fungal infections are usually found in association with
bacterial infections with fungus being the sole cause in only 15-20 percent of the cases(9).
Anatomy of the external acoustic meatus
The external ear
The external ear or the meatus acusticus externus extend from the bottom of the concha to
the tympanic membrane.  It is about 4 cms in length if measured from the tragus and 2.5
cms when measured from the bottom of the concha. It is divided into a cartilaginous and
bony part which forms a S shaped curve as it proceeds towards the tympanic membrane.
It first curves inwards, forwards and slightly upwards (pars externa) and then it passes
inwards and backwards (pars media) and finally downwards (pars interna).
The ear canal is oval and cylindrical in shape and has 2 constrictions:
 The first is at the inner end of the cartilaginous canal.
 The second is at the isthmus, in the osseous segment about 2 cms from the
concha.
5The length of the cartilaginous canal is about 8 mm in length and the osseous segment
about 16 mm in length. The cartilage is continuous with the auricular cartilage and is
deficient in the upper and the posterior part of the meatus. There are two to three deep
fissures seen in the anterior part of the cartilage.
The osseous portion is also known as meatus acusticus externus osseus. It is narrower
than the cartilaginous canal and its anterior wall is about 4mm longer than the posterior.
Its medial end is lined by a groove deficient in its superior aspect-the tympanic sulcus
where the pars tensa find its attachment (Pic 1).
The skin lining the meatus is adherent to the cartilaginous and the osseous canal wall and
is very thin and forms the epithelial layer of the tympanic membrane. The subcutaneous
tissue of the cartilaginous portion is thick and contains numerous wax secreting
ceruminous glands which resemble sudoriferous glands.
Blood supply- branches from the posterior auricular, internal maxillary and temporal
arteries.
Nerve supply- nerves are chiefly derived from the auriculotemporal branch of the
mandibular nerve and the auricular branch of the vagus.
Fungi
Fungi are eukaryotic organisms comprising of moulds, yeasts, mushrooms and are almost
found everywhere. The word Fungi is derived from the Latin word fungus which has its
origin from the Greek word Sphongos which means sponge. The Egyptians have
documented the presence of fungi as early as 4500 B.C. A number of hieroglyphic
6depictions of plants (many of which are psychedelic) on walls and within texts could be
found throughout Egypt. Temples with countless pillars shaped like huge mushrooms
with tall stems, umbrella caps, and mushroom engravings were also distributed all over
the country (Pic 2)
They differ from plants in that they lack cellulose. Classically fungi are broadly divided
into 2 groups, the yeasts and the moulds.
Among the medically important fungi, the Aspergillus genus is the most common fungi
causing otomycosis (10). It is present worldwide and niger is the most common species.
The niger species are referred to as black aspergillus as they produce black colonies. The
niger species have 8 morphologically distinct taxa (11).  Other species of Aspergillus like
the awamori and tubingenisis (2) have also been isolated in otomycosis.
Fungi reproduce both sexually and asexually. Sexual reproduction involves meiosis.
Certain species of fungi mate with the individuals of opposite mating type while others
mate with themselves or individuals of the same mating type, the former are known as the
heterothallic and the latter, the homothallic (12).
The asexual phase involves formation of spores, also known as conidia. Spores maintain
clonal populations and help in rapid dispersion of the fungus (13). This is a very
significant clinical finding in diagnosing a case.
Under unfavorable conditions, fungi form spores. Fungal spores have a characteristic
robust cell wall which help in its biological behavior.(Good day -1994) The spores have
germ tubes which germinate from the sides and elongate to form cylindrical filaments
which are called as hyphae (Pic 3).
7The hyphae get entangled and form mycelia. The hyphae have numerous compartmental
walls known as septae. These compartments communicate with each other for the passage
of nutrients and organelles such as nuclei (14).
The structure of the filamentous fungal cell wall
Polysaccharides and glycoproteins are the two components of the cell wall of which
polysaccharides contributes a major portion. The fungal cell wall is not homogenous and
is composed of different layers, a feature which is highlighted with electron microscopy.
The four components of the cell wall include the beta (1-3) glycan, beta(1-6 glycan),
chitin(N-acetyl glucosamine) and glycoproteins. The beta glycans and the chitins form the
inner fibrous layer and the glycoproteins form the more flexible outer layer (14) (Pic 4)
Hydrophobins are a group of proteins which protect the hyphae and spores from
aggregating and render the fungi resistant to desiccation.
Mechanism of growth of fungal hyphae
Fungal hyphae grow by tip extension via apical growth. These apices have vesicles rich in
carbohydrate rich monomers and cell wall synthetase enzymes. Increased branching of
the hyphae are seen during increased nutritional supply. Many survival strategies are
available for fungus during starvation, the main two being (14) :
a. Autolysis
b. Cryptic growth
Autolysis is a process in which proteolytic activity of fungi increases significantly,
leading to self-digestion. White et al proposed that the digestion of the fungal cell wall
8was by hydrolytic enzymes. The hydrolytic enzymes broadly fall into three categories-
chitinases, gluconases and proteases. These enzymes are inhibited by feedback
mechanism as the number of end products increase. The end products are used for
providing nutrition to the hyphal ends. This metabolism is known as endogenous
metabolism (Righelato et al) and the phenomenon as cryptic growth and probably the
cause why these infections are hard to eradicate (14).
Clinically significant fungi in otomycosis
Aspergillus
Kingdom: Fungi
Phylum: Ascomycota
Order: Eurotiales
Family: Trichocomaceae
Genus: Aspergillus
In 1729, Michelle described the microscopic structure of an organism which looked
similar  to a device used by Roman clergy men to sprinkle holy water during the liturgy –
The Asperga (Ainsworth 1976)(15). It is derived from the Latin word, “Thou will
sprinkle”. These organisms are saprophytes and grow on decaying vegetation, in this
instance dead human skin. The spores of Aspergillus are components of aerosols and they
disperse themselves with the air current to get deposited over either a solid or liquid
media. They then germinate (Kanaani et al. 2008). This ability to be carried in air currents
9and be dispersed anywhere makes them ubiquitous (14). The fungi are heterotrophic and
differ in the feeding mechanisms from other scavengers in that they secrete acids and
enzymes into the surrounding environment and digest organic material. Their hyphal tips
grow into and through food substrate and derive nutrition.
Microscopic Features
The basic morphology of all the species of Aspergillus is the same. There are some
features unique to certain species and some similar features (16)(17)(18).
The common features
They have septate and hyaline hyphae. The conidiophores arise from the basal foot cell
on the supporting hyphae and terminate in a vesicle at the apex. Vesicle formation is
typical of aspergillus. Morphology and colour of the conidiophores varies among species.
The phialides are flask shaped structures which when they completely cover the vesicle,
are called radiate head. When they partially cover the vesicle, they are called columnar
head. The conidia form radial chains around the phialides.
Aspergillus Niger
This filamentous Ascomycota fungus (Pic. 5) is ubiquitous in the environment and has
been involved in opportunistic infections of humans. It is a citric acid producer and is
attributed to be one of the most common species isolated in otomycosis. It was discovered
by Van Tiegham in 1867. The microscopic morphology describes the hyphae as septate
and hyaline. The conidial spores are radiate initially and at maturity split into columns.
They produce vesicles which support the conidiogenus phialides and are hence called
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biseriate. The conidiophores are about 400-3000 micrometer, smooth and hyaline and
become dark at the apex which terminate in a globose vesicle each of 30-75 micrometer
in diameter. The entire vesicle is covered with metulae and phialides. The conidia are
rough, black, globose and measure about 4-5 micrometer in diameter (19).
When grown on potato dextrose agar at 25°C, they initially become white, then quickly
turn black and start producing conidia. In agar medium the growth is initially pale yellow
and may produce fissures on the same.
The Aspergillus niger 'aggregate' is a complicated taxonomic subgroup containing 8
morphologically indistinguishable taxa: Aspergillus niger, Aspergillus tubingensis,
Aspergillus acidus, Aspergillus brasiliensis, Aspergillus costaricaensis, Aspergillus
lacticoffeatus, Aspergillus piperis, and Aspergillus vadensis. The awamori, first described
by Nakazawa, has been compared taxonomically with other black aspergilla and recently
it has been considered a synonym of A. niger (11).
Aspergillus fumigatus
The fumigatus species was first described by Fresenius in 1863. The hypha is septate and
hyaline and it belongs to the thermophilic group of fungi. Their conidial heads are
columnar in an undistributed culture and their conidiophores are uncolored, smooth–
walled and have a length of 300 micrometers. They are uniseriate with compact phialides
seen on the upper portion of the vesicle. The conidia are subglobosal with a diameter of
2-3.5 micrometer and are smooth and finely roughened (20)(15)(21).
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On dextrose agar at 25 degrees, they are smoky gray–green and have a cottony to granular
texture. Atypical colonies are white with sparse conidiation. Their hyphae in tissue
usually demonstrate a branching at 45 degrees although this may vary.(20)(19)(21).
Aspergillus flavus
This member of the Aspergillus genus has a remarkable ability to survive in high
temperatures, thus making it a predominant organism in the Middle East, Africa and
South East Asia. In the northern hemisphere it is seen in the harvest time. The fungi can
grow anywhere between 25-42 degrees Celsius and may grow at an optimal temperature
of 37 degrees. It is thermo tolerant up to 55 degrees Celsius. It accounts for about 50-80%
of ENT and ocular related cases like sinusitis, keratitis and cutaneous infections. They are
the pathogens implicated in the production of aflatoxins.
On microscopy, the hypha show septations and have a 45 degree angle branching. The
conidial heads are arranged in a radiate manner and lose their columnarity with age .Their
conidiophores are about 400-850 micrometers in length and 15-20 micrometers wide. The
conidia are uncolored and coarsely roughened. They are biseriate and have metulae
covering the entire vesicle. At times they may be uniseriate, pale green and may be
conspicuously echinulate. Cleistothecium are usually absent in this species (22)(23)
Candida
Kingdom: Fungi
Phylum: Ascomycota
Subphylum: Ascomycotina
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Class: Ascomycetes
Order: Saccharomycetales
Family: Saccharomycetaceae
Genus: Candida
This yeast is the most common cause of opportunistic mycoses in the world, and usually
colonizes skin and the mucous membrane. It appears in either a mitosporic or a
teleomorphic state to produce asexual spores and consists of about 150 species of which 6
are known to cause disease in humans. The most important and frequently encountered
species is the albicans. The other species encountered are Candida tropicalis, Candida
glabrata, Candida parapsilosis, Candida krusei, and Candida lusitaniae. There has been a
recent surge of  infections caused by the non albicans candida species, the Candida
glabrata and Candida krusei(24)(25)(26)
Pathogenicity and clinical significance
The candida species cause candidiasis and this disease has an extreme diverse spectrum,
affecting almost any system or organ of the body. They have an ability to adhere to the
host cell, produce enzymes such as aspartyl proteases and phospholipase enzymes and
change from the yeast to the hyphal state(27)(28)(29).
This is the most commonly isolated yeast in human disease and causes both systemic and
superficial infection. There are reports of this organism causing infection of the cornea,
nail, ear and blood stream. (30)(31)(32). It is also the predominant species in fungal
biofilms on medical devices.(33)
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The macroscopic and microscopic appearance
Macroscopic morphology- On Sabourauds dextrose agar at 25°C the colonies are white
to cream, soft, smooth and wrinkled. The isolate grows at 42°C on media containing
cycloheximide.
Microscopic morphology- On cornmeal following 72 hours incubation at 25°C, Candida
show abundant branched pseudohyphae. True hyphae with blastoconidia in a grape like
cluster are present. On extended incubation, terminal chlamydoconidia are seen (19) .
(Pic.6.)
Candida tropicalis
Macroscopic morphology of Candida tropicalis
On Sabourauds dextrose agar, Candida tropicalis colonies are cream-colored with a
slightly mycelial border. They produce a thin surface film and bubbles when grown in
Sabourauds broth (17)(19).
Microscopic morphology of Candida tropicalis
On cornmeal tween 80 agar and at 25°C after 72 hours, it produces oval blastospores
which are located along the long pseudohyphae. The blastospores may appear singly or in
clusters. The pseudohyphae branch abundantly. Candida tropicalis may also produce true
hyphae (17)(19).
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Commensals in the ear
The commensals residing in the ear of a normal individual are the Staphylococcus
epidermidis, Corynebacterium spp, Bacillus spp, Gram-positive cocci (Staphylococcus
aureus. Streptococcus spp, non-pathogenic micrococci), Gram negative bacilli
(Pseudomonas aeruginosa, Escherichia coli, Haemophilus influenza and Moraxella
cararralis) coli, Haemophilus influenzae, Moraxella cararralis) and mycelial fungi of the
Aspergillus genus or yeast-like fungi, particularly Candida spp. The pathology sets in
once there is disharmony among these organisms(34).
Otomycosis
Definition: Otomycosis is a superficial, sub-acute or chronic infection of the outer ear
canal, usually unilateral and characterized by inflammation, pruritus, pain and
scaling(35).
Andral and Gavarret in 1843 and Mayer in 1844 first described fungal infections of the
external auditory canal. Virchow suggested the term ‘otomycosis’ (3)
Gregson and La Touche stated that fungi were secondary invaders and that bacterial
infection paved the way for fungus infection by providing a favorable degree of humidity.
Their study showed that candida caused the disease in half their patients (36). Yet in
another study by Ismail (1962) Kinery (1965), Mac Gonigle and Jillson, aspergillus was
the predominant fungi grown.
There has been an increase in the prevalence of otomycosis in the recent years much
blamed to the usage of antibiotic ear drops. Quinolones especially appears to have
15
increased the risk of otomycosis (7). Persistent otorrhoea in spite of topical antibiotic
therapy should raise a suspicion of otomycosis.
The prevalence of otomycosis has been reported to be as low as 9% of cases of otitis
externa, and as high as 30.4% in patients presenting with symptoms of otitis or
inflammatory conditions of the ear(5). It is seen more frequently in adults than in children
(37).It has been estimated that cases of otitis externa make up between 5 and 20% of all
otological consultations; the etiology of the majority is bacterial, only 15-20% is
attributed to fungi (9). Mixed infections are generally scarce as fungal flora tends to
inhibit the bacterial kind. The high incidence of Aspergillus niger and flavus to occur
alone is because of their ability to produce local antibiotic (proved in vitro) (23).
Otomycosis or fungal otitis externa is classified into:
a) Acute       b) Sub-acute    c) Chronic
Pathophysiology of fungal infection
Natural barrier
The skin helps prevent otomycosis by providing an intact mucosal surface and by
production of secretions from sweat, sebaceous and ceruminous glands. These secretions
provide an acidic pH, which are bacteriostatic and fungistatic. Various predisposing
factors include humid climate, instrumentation, immunocompromised host, recently used
antibiotic or steroid ear drops (5). The constant lateral migration is a way of defense by
removal of residing microbes. The external auditory meatus has a lining of skin similar to
that of other parts of the body.
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However, there are dissimilarities:
1) The external auditory canal resembles a skin lined culture tube where it is exposed
to the atmosphere by only a small inlet. This may provide optimum conditions for
growth of fungi and bacteria.
2) The skin is closely applied to the perichondrium and periosteum, so there is little
room for lateral expansion and hence edema is accompanied by intense pain.
3) The hair follicles sweat, ceruminous and sebaceous glands are confined entirely to
the outer third of the ear canal. Ceruminous glands are modified sweat glands
filled with fat droplets and brown pigment granules which form ear wax and
hence differ from an apocrine gland. Sweat contains acid sodium phosphate which
renders it an acidic pH of 4.7 to 7.5 (West and Todd, 1961) that hinders fungal
growth. However this becomes alkaline in the presence of excessive sweating
(Macleod and Muende, 1946) thus explaining the  reason why tropical ear wax
fails to provide the protective sleeve normally attributed to it in temperate
conditions(38)
In addition, irrigation easily removes the oliferous form of wax, which is associated with
swimming and diving (38).
Otomycosis has close relation to the histology and the physiology of the EAC. The canal
is lined with a stratified keratinized squamous epithelium that continues along the
external face of the tympanic membrane. The interior tympanic recess, medial to the
isthmus, tends to accumulate remains of keratin and cerumen and is a difficult area to
clean. This could probably be why this disease recurs. The skin is the thickest in the
cartilaginous canal (0.5 to 1 mm) and very thin (30 to 50 microns) in the bony canal (the
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internal third). It is more adherent in the external segment which in turn is hairy and has
numerous sebaceous and ceruminous glands.
The glandular secretions and the flaked cellular epithelial elements form an acidic
ceruminous substance which is impermeable to water and protects the skin of the canal.
Predisposing factors (39)
Trauma
Relative high degree of humidity
Epithelial debris in various stages of breakdown
High temperature nearing the human body temperature
Pregnancy
Use of systemic steroids
Presence of open mastoid cavities
Hearing aids with occlusive moulds (7).
The recurrences
When fungus is present, it is temporarily overgrown by bacteria, and is often left
untouched by the drops used and hence needs only a sufficient lapse of time to develop
further to recommence the cycle.
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The "recurrences" are due to the  sub-epithelial mycotic spores mainly left in the fissures
of the ear canal which remains untouched and therefore, unattacked, and grow to produce
the clinical condition repeatedly. This in turn, due to epithelial maceration and
desquamation, predisposes to repeated bacterial invasion. The otalgia usually brings the
patient back for treatment.  These observations make it necessary to tackle this condition
in two phases
a) The secondary acute external otitis and its complications
b) The underlying mycosis.
Meticulous cleansing of the ear canal is an absolute prerequisite in both the phases. It is
certain that no medication introduced into the canal will be efficacious if exudate,
epithelial scales, and debris remain. It has been observed consistently that the lack of
complete cleansing has made the difference between success and failure in treating this
problem. "Fungi grow in the presence of moisture."  Hence there was fear in using water
to irrigate the ear but studies have shown that there is absolutely no danger in this
procedure(38)(37). Successful treatment outcome was defined as resolution of all
evidence of fungal infection on physical examination. Residual disease was defined as a
condition that failed to respond to the initial choice of treatment. Recurrent disease was
defined as a condition that occurred in patients who had resolution of disease after initial
treatment but recurred in the same ear at a later date.
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Clinical presentation of otomycosis
Patients may present with either one or more of the symptoms and signs below( Table 1):
Symptoms (2)(5) Signs
Pruritus Tragal tenderness
Otalgia Canal wall edema and erythema
Ear fullness Tympanic membrane perforation
Ear discharge Otorrhoea
Tinnitus Fungal debris in the canal (Pic.7.)
Hearing loss
Tab.1.
Otomycosis is confirmed by the presence of aseptate mycelium, septate mycelium,
aspergillus conidia, fruiting bodies, yeast and pseudohyphae. The presence of fungal
elements in stained smears is confirmed by fungal colonies in culture (37)
Treatment of otomycosis
Treatment is mainly directed to the proper debridement and cleaning of the ear canal and
the application of ototopical antifungal agents (40). The first fungicidal to be used was
formaldehyde (3). Invitro studies using Merthiolate (Thiomersal), Burow's solution
(Aluminium Acetate) (2%), VoSol HC(Hydrocortisone+Acetic acid), VoSol plain,
Cortisporin (Polymixin+neomycin) suspension, clotrimazole 1%, Mycostatin,
amphotericin B, ethanol 95%, miconazole, tolnaftate 1%, natamycin, and flucytosine
have been tried.  Inhibition of yeast and most of the fungi with clotrimazole was noted
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though Merthiolate was most effective (41). It however contains mercury which is
ototoxic.
The other medications used were acetic acid (42)(43)(44), cresylate otic ear drops (5),
boric acid ear drops (42) locacorten-vioform (clioquinol and flumethasone)(44) which
are proven ototoxic medications.
Certain studies also advocate the use of systemic antifungals in addition to thorough and
regular cleaning of the external auditory canal (45).
Common topical antifungals used in otomycosis
At present, there are 3 main drugs for the treatment of otomycosis - Triazoles, polyenes,
nucleoside analogues and echinocandins (not used in otomycosis) (7). Two topical azole
antifungal agents, miconazole and clotrimazole, were introduced in 1969; and was
followed by the introduction of econazole in 1974 and a parenteral formulation of
miconazole in the late 1970s. Today, these three agents remain the mainstay of topical
therapy for many dermatophytoses (7).
The triazoles
The triazoles, better called azoles comprise of clotrimazole, fluconazole and miconazole.
Azoles are a class of five membered nitrogen heterocyclic ring compounds containing at
least one other non-carbon atom that is nitrogen, sulphur or oxygen.
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Mechanism of action (46)
Azoles bind to ergosterol and create polarity in the fungal membrane causing ions
predominantly potassium, hydrogen and other molecules to leak out of the cell, leading to
the death of the cell. Azole antifungal agents prevent the synthesis of ergosterol, a major
component of fungal plasma membranes, by inhibiting the cytochrome P-450-dependent
enzyme lanosterol demethylase (also referred to as 14a-sterol demethylase or P-450DM)).
This enzyme also plays an important role in cholesterol synthesis in mammals. When
azoles are present in therapeutic concentrations, their antifungal efficacy is attributed to
their greater affinity for fungal P-450DM than for the mammalian enzyme. Exposure of
fungi to an azole causes depletion of ergosterol and accumulation of 14a methylated
sterol. This interferes with the “bulk” functions of ergosterol in fungal membranes and
disrupts both the structure of the membrane and several of its functions such as nutrient
transport and chitin synthesis (34). Many authors believe that appropriate treatment is
begun only on identification of the offending organism, whereas others are of the opinion
that specific treatment is based on the efficacy of the drug regardless of the causal agent.
Clotrimazole is the widely used azole. Clotrimazole appears to be the most effective agent
for the management of otomycosis with a reported rate of effectiveness that varies from
95-100 percent with only one retrospective study showing a low efficacy of 50%  by
Jackman et al. Its antibacterial action on the other hand helps in treating infections of
mixed origin (7)
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The mechanism of resistance to azoles
Resistance to the azole group is not reported; however strains can become resistant by the
following mechanisms(46).
Alteration in drug target-a demethylase.
Alteration in sterol biosynthesis.
Reduction in intracellular concentration of target enzyme.
Over expression of antifungal drug target.
Polyenes (7) (46) (47)
Until the discovery of azoles, the polyenes have been used in the treatment of both
systemic and local fungal infections. The polyenes exert the antifungal action by binding
to the sterol present in the fungal wall membrane. Sensitive species of fungi must contain
sterol in the outer cell wall. Amphotericin B represents the standard therapy for systemic
fungal infections.
Mechanism of action
The drug interacts with the cell wall and creates aqueous pores in the cell leading to the
loss of cell components and eventually death of the organism (7).
The nystatin preparation is the most commonly used preparation in topical ear drops.
23
Mechanism of resistance
Decrease in the total ergosterol content.
Replacement of some or all of the polyene-binding sterol.
Masking or re- orientation of existing ergosterol.
The nucleoside analogues (7)
They act by interfering with nucleotide synthesis, which is a major step in cell energy
production, metabolism and signaling.
The echinocandins (47)
It was discovered in 1970 that echinocandins were active against the candida species.
They were produced as a byproduct of fermentation of fungi. The earliest one to be used
was Cilofungin but was withdrawn because of its toxicity. The clinically accepted drug is
the Caspofungin and the emerging ones are the anidulafungin and micafungin.
Mechanism of action
The drug is directed against formation of beta (1, 3) D-glucan
Susceptible fungi- Candida and Aspergillus
These drugs are used in systemic fungal infections not in use for otomycosis. They
interfere with the cell biosynthesis production.
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Clotrimazole
History of clotrimazole
After the World II, fungal infections began to rise and and multiple attempts have been
made to counteract this threat. The first achievement was in the early 1960s when a
researcher Prof. Karl Heinz Büchel  discoverd clotrimazole, the earliet of the azoles.
Pharmacology of clotrimazole
The antifungal properties of azoles were first described in the 1960s(46). Azoles are
divided broadly into 2 groups - the imidazoles and the triazoles. Clotrimazole, an
imidazole has been used as a topical antifungal and is available  in the form of creams, ear
drops, lotions, powders, vaginal tablets and trouches(47). It has been used in combination
with steroids, local anesthetics such as lignocaine with antibacterial drugs.Though being
an antifungal it has attributed antibacterial properties(7). Resistance to clotrimazole has
been reported(46).
Chemistry of clotrimazole
Clotrimazole is produced by alkylating imidazole with o-chlorotrityl chloride in acetone,
with triethylamine as the base.(Pic.8.) It is an odorless crystalline powder insoluble in
water.
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Mechanism of action
It acts on the cell wall of the fungus and also prevents the formation of ergosterol.
Ergosterol is a major component in the fungal cell wall membrane vital for maintaining
membrane integrity and fluidity of the fungal cell. It is derived from an organic
compound squalene.
Squalene is converted to lanosterol by squalene epoxidase. Lanosterol is convertered to
ergosterol by following either of the 2 pathways, the zymosterol pathway and the
obtusifoliol pathway (47).
The primary target of the azole is the heme protein which cocatalyses the cytochrome P-
450–dependent 14 a-demethylation of lanosterol (48). There is accumulation of lanosterol
in the cell membrane leading to its instability and leakage of the cell components.
Clotrimazole when topically administered causes an increase in the permeability of the
cell membrane leading to a loss of ions predominantly K+ and H+ resulting in cell death.
The mammalian cell wall contains ergosterol, clotrimazole at therapeutic concentrations
act selectively on the fungal ergosterol and hence poses less toxicity to the mammalian
cell.
Pharmacokinetics
The absorption of the drug is less than 0.5 percent when applied topically on the intact
skin. About 3-10 percent is absorbed from the vagina.
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The absorbed drug is metabolized in the liver and excreted in the bile. When administered
orally at 200 mg, an initial rise in plasma concentration of 0.2 to 0.35 mg/ml is noted,
followed by a progressive decline.
Adverse reactions
On topical application, it may cause stinging, erythema, edema, vesication, desquamation,
urticaria and pruritus.
When applied to the vagina, patients may complain of a burning sensation, increase in
urinary frequency or skin rash.
Oral administration may cause gastrointestinal irritation.
Therapeutic Uses (47)
Clotrimazole cures dermatophytic infections in about 60 to 100% of the cases. In
cutaneous candidiasis, it achieves a cure rate of 60 percent to 100%. Recurrences are
reportedly common after therapeutic regimes.
Clotrimazole in otomycosis
Clotrimazole is used either as a 1% cream in combination with antibiotics and steroids
for fungal skin infections. It can be used in combination with 2% lignocaine in a propyl
glycerol base as topical ear drops. Multi centric studies have been done on clotrimazole in
comparison with many other antifungals and it was found to be effective and well
tolerated.
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Povidone iodine
History
A Dijon chemist Bernard Courtois discovered iodine, a natural element in 1811 (49). It is
derived from the Greek word Ioeides meaning violet because of its intense violet vapors.
It was used in the early Napoleon era where wounded soldiers were treated with seaweeds
rich in iodine. It has been used as an antibacterial and this property was first described by
Davaine in 1880(49). Hence for over 150 years, iodine has been used in the prevention of
infections and treatment of wounds.
Iodine in the form of iodophor was found to be extremely aggressive on the mucous
membrane and on the skin and only after Shelanski and Shelanski (49) detoxified iodine
by binding it to larger molecules did they overcome this adverse reaction. The iodophor
commonly used is polyvinylpyrrolidone and has been in use for the past 20 years.
Chemistry of polyvinylpyrrolidone
PVP-1 has a very complex structure and in a water soluble compound, iodine is linked by
hydrogen bonds to the synthetic polymer polyvinylpyrrolidone, a neutral, amphipathic
organic compound. Its molecular formula is C6H9I2NO (Pic 9&10). Molecular iodine in
the form of I3- is physically intercalated with PVP-I helix (Bound Iodine) via hydrogen
bonds and is in a chemical equilibrium with I2 free iodine in the solution. The equilibrium
is depicted in the following equation
(PVPH+)I3<=> (PVPH+) I-+I2
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In the aqueous medium, when equilibrium is achieved, only one in thousand part of the
iodine is released, the rest of the complex acts as a reservoir for protracted delivery (50).
Povidone- iodine essentially retains the broad spectrum activity of iodine, yet is virtually
free from the undesirable feature associated with tincture of iodine and Lugol’s solution.
Published data show that stability of PVP-iodine solutions are vastly superior to that of
iodine tincture or Lugol’s solution. Iodine is bactericidal, sporicidal, fungicidal,
protozoacidal, cysticidal and virucidal. Both gram-positive and gram-negative bacteria
are equally affected. PVP-iodine was tested for its ability to inactivate HIV virus in cell
culture system. All products had completely inactivated the virus at PVP iodine
concentration greater than 0.5% (8). A slow release of iodine from the polymer
contributes to its long lasting action and a low irritant profile. A concentration range of
PVP-1 between 3.75 -2500 ppm kill candida strains between 10-120 seconds (8).
Povidone (PVP-1) has been extensively used over the past 30 years for various clinical
purposes on the skin and the mucosa without any serious local and systemic effects. In
contrast to other antiseptics such as chlorhexidene and benzalkonium chloride, no
resistance has been detected yet .Experimental studies have proved that PVP-1 aqueous
solution shows no ototoxicity. In our hospital the use of BIPPS (bismuth iodoform
paraffin paste) for over the past 30 years has shown no ototoxicity (51). The advantages
of povidone iodine include (52)
I. Formation of a stable complex
II. Film forming capacity
III. Prolonged germicidal action
IV. Adherence to surface and non-irritating to skin and mucus membrane
V. Water solubility and hence easy formulation
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Cellular targets of povidone PVP-1
PVP-1 exerts strong oxidizing action on amino acids (NH-), Thiol (SH-), hydroxyl group
of amino acids and nucleotides. The iodine acts on the cell wall and cell organelle
membranes by strongly interacting with the double bonds of unsaturated fatty acids(50).
PVP-1 is known to kill bacteria very rapidly; the damage caused being attributed to
inactivation of bacterial enzymes and loss of nucleotides through transient or permanent
pores in the bacterial cell wall. An electron microscopic study on the clinically relevant
gram positive and gram negative bacteria was made which showed that they exhibited
rapid partitioning and coagulation of the nuclear material in the presence of PVP-1. Ecoli
and staphylococcus aureus showed no major structural change on exposure to PVP-1.
Fungi such as Candida albicans exhibited loosening of the cell wall in a rapid dose
dependent manner. However the cells remained intact without lysis or rupture. The
microscopic and the biochemical observations support that PVP-1 reacts with the cell
wall of microorganism to cause transient or permanent damage to the cell wall.
Studies (53) show a profound interaction of PVP-1 with human inflammatory and effector
cells and mediators. The biological effector molecules mediate the tissue destruction and
the facilitation of invasion of the microbes; PVP-1 interferes with this process and hence
is supportive of wound healing and repair (53). It has been shown that a diluted PVP-1
solution has more bactericidal activity than a full strength 10 percent solution. This
phenomenon is difficult to explain. Trueman stated that dilution of the iodophor results in
less linking of free iodine to the bound iodophor hence making free iodine available for
action. The amount of iodine released follows a bell shaped curve reaching a maximum
level at 7 mg/ml solution.
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The spectrum of Povidone iodine
Iodine is a topical germicidal agent effective against a wide spectrum of organisms
including bacteria, viruses, fungi (esp. Candida and Aspergillus) and protozoa. It is
available as a solution and an alcoholic tincture (54). The microbicidal activity of
povidone iodine is broad.-even after short onset times. Unlike local antibiotics or other
antiseptics no resistance develops (55).  To counter the severe hypersensitivity reactions
and systemic absorption of iodine, the compound iodophor was formulated (54).
Iodophors are compounds of iodine linked to surfactants that act as carriers and
solubilizing agents for iodine (54).  The most extensively used iodophor is the complex of
polyvinylpyrrolidone and iodine.
Jayaraja Kumar K. et al in his paper on application of broad spectrum antiseptic povidone
iodine as powerful action: a review has shown the activity against the commonly
encountered organisms especially fungi (8)
Activity of PVP iodine Vs
organisms (No. Strains)
Range of PVP iodine in
ppm available iodine
Contact of kill time in
sec.
Proteus(41) 100-2500 15-180
Staphylococcus(36) 66-2500 15-180
Pseudomonas(36) 25-2500 15-900
Streptococcus(25) 200-2500 15-30
Escherichia(23) 200-2500 30-120
Candida(8) 3.75-2500 10-120
Spores,baccillus;clostridium(
6)
10,000 2.5hours
Enterobacter(4) 1000-2500 60
Klebsiella(4) 500-2500 60
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Activity of PVP iodine Vs
organisms (No. Strains)
Range of PVP iodine in
ppm available iodine
Contact of kill time in
sec.
Clostridium(4) 1000 30-60
Shigella(3) 1000-2500 60
Corynebacterium(3) 2500 60
Diplococcus(3) 1000-2500 60
Mycobacterium(3) 1000-2500 60-120
Bacillus(3) 7.5-1000 10-30
Aspergillus(2) 1000 30
Tab.2.
Resistance to povidone iodine
Antibiotic resistance is an omnipresent problem and in the present age, heavy growth of
resistant strains demands antibiotic and disinfectant strategies in hospitals. When
compared to antiseptics like chlorhexidene gluconate and benzalkonium chloride, PVP-1
had highest activity in test strains of MRSA (methicillin resistant staphylococcus aureus),
S.marcescens, and pseudomonas aeruginosa and bacillus cepacia.
Lanker Klossner et al(56) had reported no resistance in coagulase negative
staphylococcus in patients with long term peritoneal dialysis.
These organisms, though showed cross resistance to all antiseptics did not develop
resistance to povidone iodine.(57) Schaffer in his study had proved that povidone iodine
at dilutions of up to 1/100 and with a 30 second exposure destroyed various isolates of
methicillin resistant staphylococcus aureus and highly resistant strains of enterococcus
faecium.
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Effect of organic substance on the activity of povidone iodine
There was no reducible cell count or no activity when 0.05 percent of the PVP-1 was used
in the presence of serum, but at concentrations of 0.2 to 0.5 percent showed bactericidal
activities even after the addition of serum to final concentrations of 5 to 10 percent
respectively.
The local tolerance of povidone iodine
Povidone iodine does cause irritation or damage to the oral mucosa even after prolonged
rinsing for a period of 8-10 weeks. Use of povidone iodine reduced mucositis during
antineoplastic radiation therapy in head and neck cancers.(58)
Povidone iodine does not affect epithelial growth; this has been demonstrated by E Pels et
al on decontamination of the human donor eye using povidone iodine. Decontaminating
procedures with PVP-1 solutions of 5-100 mg/ml for 2-5 minutes can be applied without
affecting the subsequent epithelial regrowth during organ culture of the corneoscleral
button (59).
It is a presumed fact that antiseptics with a good antimicrobial efficacy possess cytotoxic
activity. Examples are the triphenylmethane dyes such as the gentian violet and brilliant
green, which hinders wound healing, so also does chlorhexidene but effects do not occur
with chloramine T, silver nitrate and povidone iodine.(60) Povidone iodine if used
appropriately at a concentration of 10 percent does not cause cell damage. If combined
with detergents, it may produce cytotoxic effects. These effects do not occur on intact
skin, and hence widely used as a surgical disinfectant for hands.
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Considering sensitivity of povidone-iodine, out of 6,050 individuals who underwent a
routine patch test, only 0.73% showed an epicutaneous sensitization against povidone-
iodine and the allergy was attributed to the iodine component (60).
The adverse effects of povidone-iodine
Absorption of iodine from povidone application is enhanced when the compound is
applied to denuded surfaces, mucosal surfaces with highly absorptive capacity or
extensive areas of intact skin(54).
The compound can cause local toxicity when applied to fresh surgical wounds and the
toxicity is directly proportional to the concentration of the solution used.
Allergic reactions
When applied to the intact skin in normal individuals, the incidence of contact dermatitis
is very low, that is about 2 in 5000 applications (61).
Mutagenicity
Mutagenicity in mice and hamsters caused by povidone-iodine was tested by the
micronucleus test or the dominant lethal assay test and none of them showed any
evidence of mutagenic effect (62).
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Thyroid dysfunction
Excessive incorporation of iodine can occur in individuals treated with povidone-iodine
leading to thyroid dysfunction. Predisposed individuals include individuals with
Hashimotos disease, goiter and newborns (63).
However a number of clinical trials exist on the repeated use of povidone iodine in the
disinfection of hands and skin, mucosal antiseptics, burns and chronic wounds, eye
infections etc.(49)
The toxicity of iodine has been detected in very few cases. No ototoxicity was noted in
vivo studies when used in chronic otitis media with central perforation(51), though a
study done in guinea pigs in 1982 by Aursnes J showed a slight damage to the basal part
of the organ of Corti in ears exposed to Iodophor or Iodine for 60 minutes(63). A study
was done by Perez et al in 2000 which compared povidone-iodine, chlorhexidene and
alcohol on the vestibular and cochlear function of sand rats inner ear, which showed
povidone-iodine to have no effect on the vestibular and auditory evoked potentials as
compared to chlorhexidene and alcohol. Iodine has been used in the form (BIPP), bismuth
iodophorm paste for packing of the mastoid cavities for many years and no ototoxicity
has been observed till date, however a clinical trial is yet to be done. Thus considering the
above facts, we felt it reasonable to use this drops in otomycosis with an intact drum
where the chances of systemic absorption will be almost negligible.
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MATERIALS AND METHODS
The purpose of the study is to know if povidone-iodine is effective in treating clinically
diagnosed fungal otitis externa of the ear.
Type of study
Pilot study - Single blinded prospective randomized case control study.
Period of study - 2 years
Subjects
All patients with clinically diagnosed otomycosis, who satisfied the following inclusion
and exclusion criteria.
Inclusion Criteria:
Age group- individuals from age 15-70 years
Exclusion Criteria:
1) Age group – less than 15 years and more than 70 years
2) Chronic suppurative otitis media
3) Postoperative mastoidectomy cases
4) Malignant otitis externa
5) Uncontrolled Diabetics
6) Patients with hearing aids
7) Patients receiving chemotherapy and post chemotherapy
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Target sample size and rationale:
A sample size of 270 was calculated. Sample size calculations were based on the fact that
the primary outcome for this study was improvement in symptoms and cure. It was
estimated that 90% in the clotrimazole group will improve compared to 75% in the
povidone-iodine group. To find a 15% difference in the outcome, assuming the power to
80% and level of significance to be 5%, sample size was calculated as 135 in each arm
(total sample size = 270).
For two groups with percentages (cure rate), clotrimazole (p1) = 90% and proposed cure
rate of povidone iodine is (p2) =75%, sample size is calculated by
Sample size(n)=(Z@+Z1-b)22PQ/d2
Where P=(p1+p2)/2=(90+75)/2
Z@=type 1 error=1.96
Z1-b=type 2 error=1.28
d = difference in outcome=15
Q=100%-P=100-82.5=17.5
Therefore n=10.4x2x82x17.5/225=134.7=135 patients in each arm
Since this is the first study using povidone in clinically diagnosed case of otomycosis, we
planned to do a pilot study.
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Method of allocation concealment:
Each of the drugs were concealed in containers covered externally.
Blinding and masking: The drugs were given in an open method. The drug was
dispensed by a trained staff nurse. The principal investigator, staff nurse and the patient
were unaware of the drug being administered.
The setting, location and the methodology of the study:
The study was done in the ENT department at our tertiary hospital. All patients who
presented in the outpatient department with symptoms of pruritus of the ear, ear ache, ear
discharge, blocked sensation in the ear, tinnitus or hard of hearing, were evaluated. The
ear was inspected with an otoscope and a clinical diagnosis of otomycosis was made
based on the history and presence of matted hyphae, spores or curdy precipitate in the
external auditory canal. The patients who fulfilled the inclusion and exclusion criteria
were referred to the principal investigator.
The principal investigator re-examined these patients, visualized the ear under the
microscope (Karl Zeiss) with a 250 mm objective lens and noted the findings (Pic. 11).
Position of the otomycotic debris in the ear canal was noted as lying in the isthmus, in the
bony canal or in the cartilaginous canal. The presence of any erythema over the
cartilaginous canal and bony canal were noted and the status of the tympanic membrane
whether congested or perforated was noted .The presence of tragal tenderness or mastoid
tenderness was looked for.
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Otomycotic debris was scooped out with a sterile swab and put in a sterile test tube
containing 2 ml normal saline .The sample was immediately sent for a fungal smear. Rest
of the fungal debris was removed using a sterile suction tip.
Fungal debris were teased onto a slide and stained with gram stain. Presence of fungi and
bacteria were looked for.
The ear swabs for this study were inoculated onto Blood agar (BA), Sabouraud’s dextrose
agar (SAB) with antibiotics & thioglycolate broth. BA was incubated at 37oC in CO2
atmosphere and SAB & thioglycolate broth at 37oC for 18 hours. If there was a suspicion
of fungal growth at the point of inoculation, the plates were incubated for a further 24 to
48 hours till sporulation occurred in order to facilitate identification. Fungal growth was
identified by doing Lacto Phenol Cotton Blue (LPCB) preparation.(Pic.12 & 13)
After thorough toileting of the ear, the patient was sent to the ENT treatment room for
administration of the study drug or the control drug by the sister in charge. At the
beginning of the study itself, the drugs were serialed according to the randomization order
generated by a computer and the sister in charge was given sealed envelopes which
contained the drug to be administered to the patient in a serial order. In case of bilateral
otomycosis, the more severely affected ear was taken as the test ear.  The patient was
advised to put 3 drops of the drug into the affected ear once a day. The patient was
advised to clean his/her hands or the helper’s hands prior to the instillation. The
instillation was done with the patient lying on his non- affected side or the side with fewer
symptoms. The affected ear was placed upright and the pinna pulled upwards, backwards
and outwards to straighten the canal. The drops were instilled and the patient asked to
remain in that position for about 10 minutes.
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He /She was asked to repeat this step every day for the next 13 consecutive days.
At the end of the 2 weeks the patient was reviewed in the OPD, questioned regarding
relief, persistence or worsening of any symptoms or appearance of any new symptoms.
The ear was re-examined under the microscope and the findings were noted and the
repeat culture was taken from the ear. If there was no debris noted, a smear from the canal
wall was taken.
Outcome
A favourable outcome was said to be achieved if the patient had no symptoms, external
auditory canal was free of debris and the post treatment smear showed a normal flora or
no growth.
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RESULTS
Statistical analysis - all statistical analysis were performed using statistical package for
social science version 16.0 (SPSS Inc, Chicago ,IL)
Demographic details
Fig.1
Our study showed an equal predilection in both the genders (Fig 1).
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Fig.2.
The number of males and females in the three age groups were compared and it was
found that there is a female predominance in the first age group, a male predominance in
the second age group and equal predominance of both the genders in the third age group.
The ‘p’ value was 0.524. Since there is no significant difference between the sexes in
each age group (p value>0.05), the groups are comparable (Fig.2).
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Fig.3.
Unemployed individuals accounted for the maximum number of cases, with housewives
comprising the second most affected individuals (Fig 3).
Fig.4
74% of the individuals had involvement of the left ear, with the remaining 26% having
involvement of the right ear (Fig 4).
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Symptoms- Pre- treatment:
Variables Number of patients Percentage
Pruritus
Yes
No
26
8
76.5
23.5
Ear Discharge
Yes
No
19
15
55.9
44.1
Otalgia
Yes
No
18
16
52.9
47.1
Tinnitus
Yes
No
10
24
29.4
70.6
Deafness
Yes
No
7
27
20.6
79.4
Tab.3
Pruritus was the most common symptom seen in 76.5% of the study followed by ear
discharge, ear fullness, otalgia, tinnitus and deafness in a descending order (Tab.3.).
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Signs- Pre-treatment
Variables Number Percentage
Tragal Tenderness
Yes
No
15
19
44.1
55.9
Cartilaginous canal wall erythema
Yes
No
16
18
47.1
52.9
Cartilaginous canal wall edema
Yes
No
12
21
36.4
63.6
Bony Canal wall erythema
Yes
No
20
14
58.8
41.2
Bony Canal wall edema
Yes
No
10
24
29.4
70.6
Ear discharge in the canal
Yes
No
12
22
35.3
64.7
Tympanic membrane congestion
Yes
No
23
11
67.6
32.4
Tab.4.
Tympanic membrane congestion was found in 67.6% of the individuals, followed by
bony canal wall erythema, cartilaginous canal wall erythema, tragal tenderness,
cartilaginous canal wall edema, ear discharge in the canal, bony canal wall edema in the
descending order( Tab.4.).
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Self -cleaning and the presence of wax
Variables Number Percentage
Self-Cleaning
Yes
No
24
10
70.6
29.4
Wax
Yes
No
10
24
29.4
70.6
Tab.5.
Out of 34 individuals, 24 had history of self-cleaning and 24 had no wax in the ears. This
probably explains that wax has antifungal properties (Tab.5.).
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Microbiology – Pre treatment
Variables Number Percentage
Ear Swab Bacterial – Pre treatment
Non fermenting GNB
Staphylococcus aureus
Enterococcus
Pseudomonas aeruginosa
Klebsiella
Enterobacter species
Gram negative bacilli
Occasional gram positive cocci
Escherichia coli
Citrobacter diversus
Proteus mirabilis
Group A streptococci
Non fermenting GNB + Staphylococcus
aureus + Enterococcus
Non fermenting GNB + pseudomonas
aeruginosa
Staphylococcus aureus + pseudomonas
aeruginosa + enterobacter species +
escherichia coli
Pseudomonas aeruginosa + klebsiella
Pseudomonas aeruginosa +  enterobacter
species
Gram negative bacilli +  enterobacter
species
1
3
-
-
2
1
-
1
1
-
-
1
1
4
1
2
3
1
2.9
8.8
-
-
5.9
2.9
-
2.9
2.9
-
-
2.9
2.9
11.8
2.9
5.9
8.8
2.9
Ear Swab Fungal – Pre treatment
No growth
candida tropicalis
aspergillus niger
aspergillus flavus
yeast
candida glabrata
candida tropicalis + aspergillus niger
aspergillus niger + Yeast
aspergillus niger + candida glabrata
1
-
8
8
-
-
1
4
1
2.9
-
23.5
23.5
-
-
2.9
11.7
2.9
Tab.6.
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PRE-TREATMENT SWAB BACTERIAL FLORA
Fig.5.
In pre-treatment ear swabs, (non fermenting GNB + pseudomonas aeruginosa) accounted
for 11.8% of the cases and (pseudomonas aeruginosa + enterobacter) species and
staphylococcus aureus formed 8.8% of the cases.
Among the fungi, aspergillus niger and aspergillus flavus was most commonly isolated
(23.5%) and (aspergillus niger with yeast) formed 11.7% of the cases (Fig.19.).
Aspergillus niger was the most common fungi isolated, forming 60.86% of the isolates
either in association with other fungi or in isolation and hence was the most commonly
isolated species in our institution.
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Fig.6.
Number of individuals with pure fungal infection was 32.3%.
Number of individuals with pure bacterial infection was 32.3%
Mixed infection were seen in 35.4 percent of the individuals (Fig. 6.)
0
5
10
15
20
25
30
35
fungi
23
9
A.Njger Other fungi
49
Fig.7.
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Microbiology – Post treatment
Variables Number Percentage
Ear Swab Bacterial – Post treatment
No  growth
Non fermenting GNB
Staphylococcus aureus
Enterococcus
Pseudomonas aeruginosa
Klebsiella
Enterobacter species
Gram negative bacilli
Occasional gram positive   cocci
Escheria coli
Citrobacter diversus
Proteus mirabilis
Group A streptococci
Non fermenting GNB + Pseudomonas aeruginosa
Non fermenting GNB + pseudomonas aeruginosa +
enterobacter species
Citrobacter diversus + non fermenting GNB
Pseudomonas aeruginosa + klebsiella
Pseudomonas aeruginosa + enterobacter species
Klebsiella + enterobacter species + Enterococcus
Lost to follow-up
14
-
1
-
1
-
-
-
-
-
-
1
-
2
1
1
1
3
1
8
41.2
-
2.9
-
2.9
-
-
-
-
-
-
2.9
-
5.9
2.9
2.9
2.9
8.8
2.9
23.5
Ear Swab Fungal – Post treatment
No growth
Candida tropicalis
Aspergillus niger
Aspergillus flavus
Yeast
Candida glabrata
Lost to follow-up
23
-
1
2
-
-
8
67.6
-
2.9
5.9
-
-
23.5
Tab.7. Post –treatment bacterial swab (Tab .7.)
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Fig.8 .
Fig.9.
Patients with mixed infection comprised 7.4% (Fig.9.)
Staphylococcus
aureus
9%
pseudomonas
aeruginosa
9%
proteus mirabilis
18%
non fermenting
GNB +
pseudomonas
aeruginosa
9%
.non
fermenting
GNB +
pseudomonas
aeruginosa +
enterobacter
species
9%
citrobacter
diversus + non
fermenting GNB
9%
pseudomonas
aeruginosa +
klebsiella
28%
pseudomonas
aeruginosa +
enterobacter
species
9%
25
2
Total number of patients-27
Others
Mixed infection
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Number of patients who received candid ear drops and povidone-iodine ear drops
(fig.10.)
Fig.10.
Number of patients with residual disease – fungus
Fig.11.
After treatment with povidone-iodine nine of the smears grew bacteria, pseudomonas
aeruginosa was the most common isolate followed by enterobacter.
19
15
0
5
10
15
20
Betadine Candid
number of patients
12
6
2 1
0
2
4
6
8
10
12
14
Betadine Candid
pretreatment fungi-
number of patients
post treatment fungi -
number of patients
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After treatment with clotrimazole and lignocaine, 3 had grown bacteria, with
pseudomonas aeruginosa forming the most common isolate followed by non-fermenting
gram negative bacilli.
Considering fungal infections,
Post treatment 23 of the patients had no fungal growth, 8 were lost to follow up and 3 had
residual fungal infection out of which 2 belonged to the povidone- iodine group and 1 in
the clotrimazole group (Fig.24.).
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No of individuals who received povidone-iodine and clotrimazole with lignocaine ear
drops in each symptom profile (Tab.8.)
Variables
Drug
p – ValueClotrimazole+Lignocaine
Povidone-iodine
n % n %
Pruritus
Yes
No
11
4
73.3
26.7
15
4
78.9
21.1
1.000
Ear Discharge
Yes
No
5
10
33.3
66.7
14
5
73.7
26.3
0.036
Ear Fullness
Yes
No
10
5
66.7
33.3
9
10
47.4
52.6
0.314
Otalgia
Yes
No
5
10
33.3
66.7
13
6
68.4
31.6
0.082
Tinnitus
Yes
No
4
11
26.7
73.3
6
13
31.6
68.4
1.000
Deafness
Yes
No
3
12
20.0
80.0
4
15
21.1
78.9
1.000
Tab.8.
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Post-treatment symptoms with levels of significance between the 2 groups  (Tab.9.)
Variables
Drug
p – ValueClotrimazole+lignocaine
Povidone -iodine
n % n %
Pruritus
Yes
No
2
10
16.7
83.3
1
14
6.7
93.3
0.569
Ear Discharge
Yes
No
1
11
8.3
91.7
1
14
6.7
93.3
1.000
Ear Fullness
Yes
No
2
10
16.7
83.3
1
14
6.7
93.3
0.569
Otalgia
Yes
No
-
12
-
100.0
2
13
13.3
86.7
0.487
Tinnitus
Yes
No
1
11
8.3
91.7
-
15
-
100.0
0.444
Deafness
Yes
No
1
11
8.3
91.7
-
15
-
100.0
0.444
Tab.9.
In the symptom profile the clotrimazole group showed a resolution of symptoms in
pruritus, ear discharge, fullness, tinnitus and deafness of 83.3%, 91.7%, 83.3%, 91.7%
and 91.7% respectively. However there was a 100% resolution of otalgia.
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In the povidone-iodine group, there was complete resolution of deafness and tinnitus,
whereas pruritus, ear discharge and ear fullness had 93.3% resolution. However, the
otalgia resolved only in 86.7% of the cases.
Considering the number of individuals who received the drops in each sign profile
(Tab.10.)
Variables
Drug
Clotrimazole+Lignocaine Povidone-iodine
n % n %
Tragal Tenderness
Yes
No
7
8
46.7
53.3
8
11
42.1
57.9
Cartilaginous canal wall erythema
Yes
No
8
7
53.3
46.7
8
11
42.1
57.9
Cartilaginous canal wall edema
Yes
No
6
8
42.9
57.1
6
13
31.6
68.4
Bony Canal wall erythema
Yes
No
9
6
60.0
40.0
11
8
57.9
42.1
Bony Canal wall edema
Yes
No
3
12
20.0
80.0
7
12
36.8
63.2
Ear discharge in the canal
Yes
No
5
10
33.3
66.7
7
12
36.8
63.2
Tympanic membrane congestion
Yes
No
9
6
60.0
40.0
14
5
73.7
26.3
Tab.10.
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Post –treatment signs with levels of significance (Tab.11.)
Variables
Drug
p –
Value
Clotrimazole +
Lignocaine
Povidone -
iodine
n % n %
Tragal Tenderness
Yes
No
-
12
-
100.0
-
15
-
100.0
-
Cartilaginous canal wall erythema
Yes
No
2
10
16.7
83.3
-
15
-
100.0
0.188
Cartilaginous canal wall edema
Yes
No
1
11
8.3
91.7
-
15
-
100.0
0.444
Bony Canal wall erythema
Yes
No
1
11
8.3
91.7
1
14
6.7
93.3
1.000
Bony Canal wall edema
Yes
No
-
12
-
100.0
1
14
6.7
93.3
1.000
Ear discharge in the canal
Yes
No
-
12
-
100.0
-
15
-
100.0
-
Tympanic membrane congestion
Yes
No
-
12
-
100.0
2
13
13.3
86.7
0.487
Tab.11.
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Considering tragal tenderness, 100% had relief of the symptom using both the ear drops.
There was no statistical significance between the 2 groups (p value>0.05), hence the
groups are only comparable.
Povidone-iodine had shown 100% resolution of both the cartilaginous wall erythema and
the edema whereas the clotrimazole group showed a favorable response of 83.3% and
91.7% respectively. There was no statistical difference between the groups (p
value>0.05), hence the groups are comparable.
Bony canal erythema had resolved in 91.7% and 93.3 % of the cases respectively which
was not statistically significant (p value>0.05) and hence the two groups were
comparable.
Clotrimazole showed a 100 % resolution in the bony wall edema, ear discharge and
tympanic membrane congestion whereas povidone-iodine showed a resolution of 93%,
100% and 86.7 % respectively. Both drugs had a 100 percent cure in regard to bony wall
edema. It was no statistically significant (p>0.05) and hence the two groups were
comparable.
In view of the above findings, it can be stated that both drugs were equally efficacious in
resolving the above symptoms and signs. But this could not be established as the
statistical value was insignificant. Hence we recommend a study with larger sample size
in order to gather further information.
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DISCUSSION
Otomycosis, a common condition encountered in any ENT practice, can often be a
challenging and frustrating entity for both patients and treating otolaryngologists. Though
complications are infrequent and rarely life threatening, it often recurs and may require
prolonged treatment and follow-up. The aim of treatment is not only to cure the infection,
but also to alleviate the symptoms and signs caused by this condition. The high
recurrence is attributed to the persistence of spores.
Chronic suppurative otitis media, post-operative mastoidectomy cavities and
immunocompromised individuals are well documented predisposing factors for this
condition. Hence in our study we had excluded the above conditions and tried to analyze
if there are any other factors for otomycosis. For complete disease clearance, management
should address the underlying factors.
The basic principles of management of fungal otitis externa include effective aural toilet,
identifying the causative organism and eliminating it using the appropriate antifungal
agent. Though systemic antifungals have been attempted in otomycosis, topical
preparations are commonly used as these fungi cause superficial infections only. Frequent
relapses of otomycosis have been encountered due to the persistence of spores. Studies
have shown that sub epithelial spores persist in spite of using topical antifungal eardrops
and hence stressed the importance of longer duration of treatment and follow up (6).
However in our study, on examination after 2 weeks of treatment, no spores were
encountered. Hence we emphasize on meticulous aural toileting, especially in the region
of the isthmus and the anterior recess.
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A number of ototopical antifungal treatments have been tried in the past, these include
application of antiseptics such as gentian violet, boric acid, cresylate and aluminium
acetate (Burrows Solution) but these drugs fell out of favor in view of their ototoxicity,
when the condition was associated with a perforation.
Clotrimazole is a common antifungal of the azole group used in the treatment of
otomycosis. It is used most commonly in combination with either topical antibiotics or
steroid preparations. The drug was found to be effective in most other studies, achieving a
cure rate of 95 % (7).
We planned to look at the efficacy of 7.5 % of povidone iodine solution in the
management of otomycosis. 1% clotrimazole with 2% lignocaine in propyl glycerol base
was used as the control drug. Our primary aim was to find an alternative to clotrimazole
in the treatment of otomycosis.
We selected povidone- iodine as it is easily available and has been proven to be effective
in chronic suppurative otitis media which is one of the predisposing factors of
otomycosis. It is chemically stable, inexpensive and resistance in bacteria and fungi is yet
to be reported.
Excessive and indiscrete use of any topical antibiotic and antimicrobials may lead to the
emergence of resistant organisms. Povidone iodine overcomes this problem as there are
no studies to date showing development of resistance, which is an increasing cause of
concern in this antibiotic resistance era.
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In developing countries like India and the third world countries, where a cheaper and
effective form of medication without ototoxicity is a requisite, povidone iodine forms a
better choice.
We removed confounding factors such as immunocompromised individuals, patients
with hearing aids and tympanic membrane perforations as they would need a longer
duration of therapy as 2 weeks of treatment may not have sufficed.
In view of the demographic details of otomycosis, a retrospective study done in Shanghai
in 2010(64), concluded that females were more affected with a female: male ratio of 2:1.
A similar result was seen in a study in northern Iraq(65). However in our study we found
an equal preponderance in both the sexes. Yet another retrospective study by P. Hueso
Gutiérrez et al (34) and a study in Nigeria gave a higher male predominance to this
condition. Hence we conclude that there is no sex preponderance to this disease though a
larger sample size may be required.
Very few studies have described the sex and age distribution, and the affected individuals
mainly belonged to the 30-40 years age groups (2)(37) In our study, a larger number of
individuals belonged to  the age group 15-30  with a female preponderance. This was
however not statistically significant. Unemployed individuals were seen more affected
with the disease followed by house wives.
The various factors taken in comparison of the drugs such as the patient’s symptoms and
signs were compared with the pre-treatment and post-treatment and tabulated. This is the
first study in literature where we have graded signs and noted the resolution of signs after
the treatment and hence can propose grading of otomycosis based on the signs. The signs
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and symptoms in this study to each drug was later Chi squared and found to be
insignificant (p value>0.05) and so the groups were comparable.
Majority of our patients presented with pruritus followed by otorrhoea, ear fullness,
otalgia, tinnitus and deafness when compared with other studies such as that of Tang Ho
(5)   in which otalgia was the major symptom followed by otorrhoea and hearing loss.
Pruritus would have instigated the individual to self–clean his ear, traumatizing the
epithelium leading to maceration and causing the introduction of fungal and bacterial
organisms thus leading to infection.
In our study, repeated self-cleaning seemed to have a close relation to the absence of wax.
Majority of the patients had their left ear affected. This probably would have related to
the handedness of the general population. The general population comprises of mostly
right handed individuals. Use of the non-dominant hand would have caused more
epithelial damage and hence infection. Further studies can be done including the
handedness of the individual and ear side affected.
Looking at the microbial floral growth, studies have shown that  mixed infections are
quite rare as the fungi generally tend to inhibit bacterial flora (36).In our study of
clinically diagnosed cases of otomycosis, infection due to the mixed flora topped the list
and we propose it may be due to formation of bio-films which are known to be quite
resistant to the topical agents commonly used. This may also explain the recurrent nature
of otomycosis. Further research will be necessary to confirm this.
The commensals residing in the ear of a normal individual are the Staphylococcus
epidermidis, Corynebacterium spp, Bacillus spp, Gram-positive cocci (Staphylococcus
aureus. Streptococcus spp, non-pathogenic micrococci), Gram negative bacilli
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(Pseudomonas aeruginosa, Escherichia coli, Haemophilus influenza and Moraxella
cararrhalis) and mycelial fungi of the Aspergillus genus or yeast-like fungi, particularly
Candida spp.
Our pretreatment smears had a predominance of Non fermenting GNB and Pseudomonas
aeruginosa, and 75% of this group had association with fungus. Our studies tallied with
most of the others in isolating aspergillus niger as the most common species. When a
person developed symptoms it often denoted a dis-harmony between the pathogens and
the onset of infection.
Presence of enterococcus and enterobacter in our study suggests a faeco-aural
transmission of the bacteria.
Though both clotrimazole and povidone-iodine groups had improvement in the post-
treatment symptoms and signs, the clotrimazole and povidone – iodine group had a
residual fungal disease of 16.6 percent and hence povidone iodine had a cure rate as equal
to clotrimazole.
Povidone – iodine has shown to kill most of the bacteria in a biofilm if not all as proved
in invitro studies. However it is less effective than hydrogen peroxide in biofilms.
Hydrogen peroxide is irritative to the skin and its application to an already erythematous
ear canal may cause the patient more discomfort(66).  It causes effervescence and must be
only used under supervision. Alcohol rapidly destroyed biofilms of staphylococcus
epidermidis. Candida has known to form biofilms especially in in dwelling catheters and
studies are now suggesting biofilm formation of aspergillus species with bacteria
(67)(68)(69).There has been no literature showing biofilms as a cause for recurrent
external auditory canal infection, hence we strongly suggest that recurrence and
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persistence of disease is not just as a result of spores, but probably due to biofilm
formation.
Oral antibiotics are indicated when co existing bacterial infection results in incomplete
resolution of the canal infection or when cellulitis of the external auditory canal sets in.
Unlike other studies which compared only the symptoms and the culture, we categorized
the signs as confined to various parts of the ear canal, and the tympanic membrane and
concluded that most of the patients had tympanic membrane congestion followed by bony
and cartilaginous wall erythema.
Fungal debris was most commonly noted in the bony cartilaginous isthmus, suggesting a
defective epithelial migration and failure of normal lateral excursion in removal of the
offending organism, thus forming a nidus for fungi to thrive on.
A once a day application of the ear drops was done based on the study done earlier by
Nong et al , which showed a cure rate of 95% (7). As povidone-iodine results were
comparable with the clotrimazole group, povidone may also be applied once a day hence
increasing the patient compliance.
None of our patients developed any symptoms and signs of allergic contact dermatitis.
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CONCLUSIONS
The result of this study supports the use of Povidone-iodine in the treatment of
otomycosis, thus avoiding emergence of resistant organisms. Future studies in larger
groups of patients are necessary to see which is more effective. This study has opened a
window in the application of povidone –iodine in clinically diagnosed case of otomycosis
in humans in addition to the management of chronic suppurative otitis media.
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Pic.1.Anatomy of the ear (Adapted from the Gray`s Anatomy of the Human body.)
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Pic.2. Adapted from IMA Fungus volume 1 The history, fungal biodiversity,
conservation, and future perspectives for mycology in Egypt
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Pic.3.The structure of aspergillus  hyphae Adapted from “Surface structures and
mechanical properties of model fungus Aspergillus nidulans”
Pic.4.Schematic diagram of cell wall components  Adapted from “Surface structures and
mechanical properties of model fungus Aspergillus nidulans”
Glycoproteins-p, chitin-c, glucan-g
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Pic.5. Microscopic image (100-fold magnification) of Aspergillus niger, grown on
Sabourauds agar medium
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Pic.6.Candida albicans grown on cornmeal agar
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Pic.7. Endoscopic view of otomycosis and spores
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Pic.8.  Structure of the clotrimazole molecule
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1nm to 18 m
Pic. 9. The Poly (1-vinyl-2-pyrrolidone)-iodine complex
Pic.10.   The Image of PVP-I wrapping a single wall carbon nanotube (black in
color)
Adopted from Dr Trevor .J. Simmons
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Pic. 11. Examination of the ear under the microscope and collection of samples
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Pic.12. Aspergillus niger in LPCB Pic.13.Aspergillus flavus in LPCB
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PATIENT INFORMATION   SHEET
You are invited to participate in the research project that is explained below.
Thank you for taking time to read this information. Please make sure you have read all
the papers.
What is this research about?
This research is carried out with a purpose of finding an alternative cheaper treatment for
the treatment of fungal infection of the ear. Fungal infection is very common in this part
of our country and in this study we compare the effectiveness of povidone iodine ear
drops to 1% clotrimazole ear drops in the management of clinically proven case of fungal
infection of the ear, hence  to establish an alternative cheaper treatment to otomycosis.
Who are the researchers?
The researchers will include the doctor who will attend you and the group of doctors that
are interested in this study. The principal investigator is the doctor who will be
questioning you regarding the complaints and will examine you to see if you fall in the
criteria for the study. The principal investigator is the person you will be able to approach
in case of any queries before during or after the study.
What are the questions I will   probably be asked before being enrolled for the study?
I will be questioned regarding
1. Itching, pain, ear discharge, fullness, tinnitus in the ear
2. If the symptoms are present in one or both the ears
3. The duration of symptoms
4. My occupation
5. Whether I have been treated for the similar complaints previously and if yes if I
knew what medications
6. If I constantly self-clean my ear
7. Have I undergone any previous surgeries?
8. Am I suffering from diabetes and if yes what medications am I on and what is my
recent blood sugars like the last time it was checked
9. Whether I have undergone any chemotherapy/radiation therapy in the past
10. If I am pregnant.
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11. Do I have any known allergies to any drugs, oral or topical, if so  I may be asked
to specify
12. If I use hearing aids
13. Whether I suffer from recurrent ear discharges especially when I catch recurrent
colds and if I am in the habit of using ear drops constantly.
Why am I chosen for the study?
You are chosen as you have fulfilled the criteria for being enrolled in the study.
Can I leave the trial when I like?
Yes, you are entitled to leave the trial if you find it inconvenient .Do bring it to the
attention of the principal investigator while doing so.
How will this trial be conducted .What is expected of me?
Once you are selected for the above study, you will be subjected to examination of both
the ears under microscope. Any debris will be sent by sterile technique for examination of
fungal elements and for culture. You ears will be cleaned .You will also be explained as
what you are to do orally .If you are suffering from diabetes, a  blood test will be done to
see if your blood sugar is under good control. I will be asked to use an ear drop selected
randomly .This ear medications will be one of the two drugs in the study, one of which
will be an established cure for the disease and the other the drug under experimentation.
You are required to instill in this ear 3 drops once a day with the affected ear facing
upward for a period of 10 minutes. This will be continued for the next two weeks.
You will be expected to come after 2 weeks to the OPD where you will be re-examined.
What is the duration of the trial? Am I supposed to be hospitalized?
The total duration of the trial is a period of 2 weeks. In the two weeks I am to visit the
principal investigator freely if I have any queries or any reactions to the drug.
If you give us consent by signing on the consent form we plan to publish the result.
What happens to my treatment when the trial is over?
Once the trial is over, if you have found to be benefited from the medication you may
continue the treatment, but if the disease still persists you will be put on an alternative
proven therapy for otomycosis
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Informed Consent form to participate in a clinical trial
Study Title: Effectiveness of 7.5% povidone iodine ear drops as compared to 1
%clotrimazole ear drops in the treatment of otomycosis.
Study Number:
Subject’s Initials: _________ Subject’s Name: ________
Date of Birth / Age:_______
(i) I confirm that I have read and understood the information sheet dated _________ for
the above study and have had the opportunity to ask questions. [ ]
(ii) I understand that my participation in the study is voluntary and that I am
free to withdraw at any time, without giving any reason, without my medical care or legal
rights being affected. [ ]
(iii) I understand that the Sponsor of the clinical trial, others working on the Sponsor’s
behalf, the Ethics Committee and the regulatory authorities will not need my permission
to look at my health records both in respect of the current study and any further research
that may be conducted in relation to it, even if I withdraw from the trial. I agree to this
access. However, I understand that my identity will not be revealed in any information
released to third parties or published. [ ]
(iv) I agree not to restrict the use of any data or results that arise from this study provided
such a use is only for scientific purpose(s) [ ]
(v) I agree to take part in the above study. [ ]
Signature (or Thumb impression) of the Subject/Legally Acceptable
Representative:_____________
Date: _____/_____/______
Signatory’s Name: _________________________________
Signature of the Investigator: ________________________
Date: _____/_____/______
Study Investigator’s Name: _________________________
Signature of the Witness: ___________________________
Date:_____/_____/_______
Name of the Witness: _____________________________
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PROFORMA Study number
Name                                            Age               Sex                           Hospital number
.
Address .                           Phone Number- Study ear-
Presenting complaints
Symptoms Pre treatment
Yes-1        No-0
Post treatment
Yes-1          No-0
Itching
Pain
Ear discharge
Fullness
Tinnitus
Hearing loss
Past medical history
Past surgical history
Personal history
Self-cleaning/socioeconomic status
ENT EXAMINATION
Signs Pre treatment
Yes-1        No-0
Post treatment
Yes-1               No-0
Tragal tenderness
Cartilaginous wall erythema
Cartilaginous edema
Bony canal wall erythema
Bony canal wall edema
Ear discharge
Fungal debris in the canal
Tympanic membrane
congestion
Tympanic membrane -
Perforation
Final diagnosis-
Adverse effects-
Ear-Swab culture- pre and post treatment
Pre-treatment ear swab Post-treatment ear swab
Fungi
Bacteria
Fungi
Bacteria
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S NO
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
H NO
514260A
878329D
711159D
771117C
105225D
812850d
830958D
377998D
402773B
922773O
088778b
909480D
247117D
911123D
209306B
328625C
363675B
978308A
462975d
543253d
708649c
946504d
242414C
267243D
052487A
315555a
974855d
976867d
986498D
971827d
005446F
858508B
OCPN
Clinical virologist
Business man
Housewife
Housewife
Business man
Housewife
Housewife
Driver
Driver
Attender
Retired
Housewife
Driver
Student
Student
Student
Student
Unemployed
Unemployed
Unemployed
Unemployed
Unemployed
Unemployed
Housewife
Retired
Farmer
Housewife
Mill worker
Housewife
Self employed
Student
Unemployed
AGE
25
45
57
36
30
75
24
43
37
24
50
27
47
23
17
22
15
53
39
39
23
36
29
29
60
70
20
52
56
33
21
40
SEX
F
M
F
F
M
F
F
M
M
M
M
F
M
F
M
M
F
M
F
F
F
F
M
F
F
M
F
M
F
M
F
M
E_S
1
0
1
1
1
0
0
0
0
0
1
0
0
0
1
0
1
0
0
0
0
0
1
0
1
0
0
0
0
0
0
0
ITCH
1
1
1
1
1
1
1
1
1
1
1
0
1
1
1
1
0
1
1
0
1
1
1
1
1
1
0
0
1
0
0
0
PN
1
0
0
1
0
1
1
0
1
0
1
1
1
0
0
0
1
0
0
1
0
1
1
1
1
1
0
0
0
1
0
1
ED
0
1
1
1
1
1
1
1
1
0
1
1
0
1
1
0
1
0
0
0
0
1
0
0
1
0
1
0
1
0
1
0
EF
1
1
1
1
1
1
0
0
1
1
1
0
1
0
1
1
0
0
1
0
0
0
0
1
1
1
1
0
1
1
0
0
TN
0
1
1
0
0
0
0
0
1
0
0
0
1
1
0
0
0
0
0
0
0
0
0
1
1
1
0
1
1
0
0
0
DF
0
1
1
1
0
0
0
0
1
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
1
0
0
0
SE_CLN
0
1
1
0
1
1
1
1
1
1
1
1
1
1
1
0
0
1
1
1
0
1
1
1
0
1
1
1
1
0
1
0
TRG_T
0
0
0
0
0
1
1
0
1
1
1
0
1
0
1
0
1
0
0
0
0
1
0
1
1
1
1
1
0
1
0
0
CCW_R
0
0
1
0
0
1
1
0
1
1
1
1
0
0
1
0
1
0
1
0
0
1
0
1
1
0
0
1
0
1
0
0
33
34
015505F
017101f
Unemployed
Unemployed
65
27
M
M
0
0
1
1
1
0
1
0
0
0
0
0
1
0
0
0
0
0
1
0
S NO
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
H NO
514260A
878329D
711159D
771117C
105225D
812850d
830958D
377998D
402773B
922773O
088778b
909480D
247117D
911123D
209306B
328625C
363675B
978308A
462975d
543253d
708649c
946504d
242414C
267243D
052487A
315555a
974855d
976867d
986498D
971827d
005446F
858508B
CCW_E
0
0
1
0
0
1
1
0
1
1
0
0
0
0
1
0
1
0
0
0
0
1
0
1
1
0
0
1
0
0
0
0
F_DBR
1
1
1
1-bony canal
0
1-otomycotic debris in bony cartilaginous junction
1-black colonies in bony canal cartilaginous junction
1-fungal debris
1-black colonies adjacent to tm
1-black colonies
1-black colonies
1-whitish debris at isthmus
1-black colonies-adjacent to tm
1-whitish debris at isthmus
1-curdy white ppt
1-curdy white ppt
1-whitish debris at the isthmus
1-wax with black and white colonies
1-white debris in bony cartilaginous junction
1-bony canal
1-black colonies
1
1-black colonies
1-whitish curdy ppt
1-white colonies in bony canal wall
1-white  and black colonies in bony canal
1
1
1-debri-black in deep bony canal
1-white debris in bony cartilaginous junction
1-debri-black in deep bony canal
WAX
0
0
0
0
0
1
0
0
0
0
1
0
1
1
0
0
0
1
0
0
0
0
0
0
1
0
0
1
1
1
0
0
BC_R
1
0
1
1
1
1
1
0
0
1
0
1
1
1
1
1
0
1
0
0
0
0
0
1
0
1
1
1
1
0
0
0
BC_E
0
0
0
1
0
1
1
0
0
0
0
0
1
1
1
1
0
0
0
0
0
0
0
1
0
0
0
1
1
0
0
0
DSCRG
0
1
1
0
1
1
1
0
1
1
1
0
0
0
1
0
0
0
0
0
0
1
0
1
0
0
1
0
0
0
0
0
TMC
1
1
1
1
1
1
1
0
1
0
1
1
1
1
1
1
0
1
0
0
0
1
1
1
0
1
1
1
1
0
0
0
ESS_F
4,2
1,2
2
2
2
3
2
2
3
3
2,4
3
5,2
3
2
3
3
0
2
4,2
4,2
PPN
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
33
34
015505F
017101f
1
0
1-black colonies in bony canal wall
1
1
0
1
1
0
0
0
0
0
1
3
2
0
0
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1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
H NO
514260A
878329D
711159D
771117C
105225D
812850d
830958D
377998D
402773B
922773O
088778b
909480D
247117D
911123D
209306B
328625C
363675B
978308A
462975d
543253d
708649c
946504d
242414C
267243D
052487A
315555a
974855d
976867d
986498D
971827d
005446F
858508B
PPN
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
PED
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
1
0
PEF
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
1
1
0
0
0
0
0
PTN
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
PDF
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
PTRG_T
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
PCCW_R
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
1
0
0
0
0
0
0
PCCW_E
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
PBC_R
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
1
0
0
0
0
0
0
0
PBC_E
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
PF_DBR
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
1
0
0
0
0
0
0
0
PDSCRG
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
P_TMC
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
P_TMP
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
33
34
015505F
017101f
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
S NO
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
H NO
514260A
878329D
711159D
771117C
105225D
812850d
830958D
377998D
402773B
922773O
088778b
909480D
247117D
911123D
209306B
328625C
363675B
978308A
462975d
543253d
708649c
946504d
242414C
267243D
052487A
315555a
974855d
976867d
986498D
971827d
005446F
858508B
PESS_F
0
0
0
0
3
0
2
3
0
0
0
PESS_B
5,6,3
4,6
4,5
2+
4,6
1,4
10, 1
6, 4
4
1,4
1,4, 6
11
Drug
1
2
1
2
2
2
2
2
1
1
2
2
2
2
1
1
2
1
1
1
1
2
2
2
1
2
1
1
2
1
2
2
33
34
015505F
017101f
0
0
2
1
